Dyadic International (DYAI) EPS (Basic) Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) EPS (Basic) Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.38 Mn | 10.42 Mn | - | 8.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 8.12% |
| Dec 31, 2025 | 14.92% |
| Sep 30, 2025 | 3.96% |
| Jun 30, 2025 | 20.35% |
| Mar 31, 2025 | 11.60% |
| Dec 31, 2024 | 30.11% |
| Sep 30, 2024 | 63.90% |
| Jun 30, 2024 | 21.22% |
| Mar 31, 2024 | 91.58% |
| Dec 31, 2023 | -0.27% |
| Sep 30, 2023 | 14.91% |
| Jun 30, 2023 | 7.78% |
| Mar 31, 2023 | 5.69% |
| Dec 31, 2022 | -5.53% |
| Sep 30, 2022 | -0.66% |
| Jun 30, 2022 | -5.00% |
| Mar 31, 2022 | -6.02% |
| Dec 31, 2021 | -101.46% |
| Sep 30, 2021 | -28.74% |
| Jun 30, 2021 | -34.72% |